Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01439373 · ClinicalTrials.gov registry record · Phase 2
Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT01439373 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 16 participants.
The verdict
NCT01439373, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
GSK2336805 is a hepatitis C virus (HCV) NS5A inhibitor being developed for the treatment of chronic hepatitis C (CHC). This study will assess the safety, antiviral activity, and pharmacokinetics of GSK2336805 alone and in combination with peginterferon alfa 2a and ribavirin in subjects with chronic hepatitis C (CHC).
Interventions
- DRUG Ribavirin
- DRUG Pegylated interferon alfa-2a
- DRUG GSK2336805
- DRUG GSK2336805 Matching Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2011-07-07 |
| Est. Completion | 2011-12-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01439373
The ClinicalTrials.gov registry entry for NCT01439373 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Ribavirin is the first listed.
NCT01439373 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01439373 about?
NCT01439373 is a clinical study titled "Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects". GSK2336805 is a hepatitis C virus (HCV) NS5A inhibitor being developed for the treatment of chronic hepatitis C (CHC). This study will assess the safety, antiviral activity, and pharmacokinetics of GSK2336805 alone and in combination with peginterferon alfa 2a and ribavirin in subjects with chronic ...
What is the current status of trial NCT01439373?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2011-07-07. Estimated completion is 2011-12-05.
What interventions are being tested in trial NCT01439373?
The interventions under investigation include: Ribavirin (DRUG), Pegylated interferon alfa-2a (DRUG), GSK2336805 (DRUG), GSK2336805 Matching Placebo (DRUG).
Who is sponsoring clinical trial NCT01439373?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.